Hyundai Bioscience Co Ltd
048410
Company Profile
Business description
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.
Contact
150 North-Ahyun Road
3rd Floor Academic Cooperation Building
Ehwa Women’s University
Seodaemun-gu
Seoul
KORT: +82 7070080114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
69
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,037.40 | 47.70 | -0.53% |
| CAC 40 | 8,103.58 | 0.27 | -0.00% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,710.97 | 20.19 | -0.04% |
| FTSE 100 | 9,870.68 | 18.54 | -0.19% |
| HKSE | 25,887.33 | 68.40 | 0.26% |
| NASDAQ | 23,593.10 | 20.21 | -0.09% |
| Nikkei 225 | 50,663.04 | 87.35 | -0.17% |
| NZX 50 Index | 13,525.99 | 3.07 | -0.02% |
| S&P 500 | 6,929.94 | 2.11 | -0.03% |
| S&P/ASX 200 | 8,731.50 | 45.20 | -0.52% |
| SSE Composite Index | 3,975.92 | 12.24 | 0.31% |